General MedicationsSUBCUTANEOUSStandard
RASUVO
METHOTREXATE
Standard Dose
7.5MG/0.15ML (7.5MG/0.15ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview RASUVO is listed in Drugs@FDA under application 205776 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 7.5MG/0.15ML (7.5MG/0.15ML) Sponsor MEDEXUS Submission history Latest submission status date: 2020-03-11 00:00:00.
Structured Monograph
Clinical summary
Approval overview RASUVO is listed in Drugs@FDA under application 205776 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient METHOTREXATE Form and strength SOLUTION;SUBCUTANEOUS - 7.5MG/0.15ML (7.5MG/0.15ML) Sponsor MEDEXUS Submission history Latest submission status date: 2020-03-11 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.